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Abstract
When compared to spleen or lymph node cells, resident peritoneal cavity cells respond poorly to T
cell activation in vitro. The greater proportional representation of macrophages in this cell source
has been shown to actively suppress the T cell response. Peritoneal macrophages exhibit an
immature phenotype (MHC Class IIlo, B7lo) that reduces their efficacy as antigen presenting cells.
Furthermore, these cells readily express inducible nitric oxide synthase (iNOS), an enzyme that
promotes T cell tolerance by catabolism of the limiting amino acid arginine. Here, we investigate
the ability of exogenous T cell costimulation to recover the peritoneal T cell response. We show
that CD28 ligation failed to recover the peritoneal T cell response and actually suppressed
responses that had been recovered by inhibiting iNOS. As indicated by cytokine ELISpot and
neutralizing mAb treatment, this “co-suppression” response was due to CD28 ligation increasing
the number of IFNγ-secreting cells. Our results illustrate that cellular composition and cytokine
milieu influence T cell costimulation biology.
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INTRODUCTION
Collaboration between antigen presenting cells (APC) and T lymphocytes is a key
checkpoint in the regulation of adaptive immunity. T cell activation requires that APCs
provide two signals; processed (peptide) antigen complexed with the Class II major
histocompatibility complex to engage the TCR (signal 1) and a costimulatory signal via
CD80/86 (B7) engagement of CD28 on the T cell (signal 2).1,2 Since the TCR and CD28 are
expressed constitutively by resting/naïve T cells appropriate APC expression of Class II
MHC and B7 molecules is a major checkpoint for controlling T cell activation. Improper
expression of these receptor ligand combinations can promote T cell anergy or apoptosis.3
The great majority of costimulation studies are conducted in vitro with low APC:T cell
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tratios inherent to the natural composition of conventional lymphoid tissue.4 There has been
little investigation of the effect high APC:T cell ratios could have on T cell activation. This
is important to consider because of the paralyzed T cell function seen in tumor
microenvironments enriched with immunosuppressive, myeloid cells.5
High myeloid: T cell ratios temper T cell function, both at the end of normal immune
responses and in tumors where essential T cell effector functions have been abrogated.6–11
APCs dampen T cell function by several means, including the expression of enzymes that
consume critical amino acids, production of immunoregulatory hormones and cytokines, and
generation of regulatory T cells.7,9,12 We have shown that cultures of peritoneal cavity
(PerC) cells inherently have high macrophage (Mφ) to T cell ratios (Mφ:T). 4,13 IFNγ
released by activated T cells triggers the Mφs to express indoleamine 2,3-dioxygenase (IDO)
and inducible nitric oxide synthase (iNOS), enzymes that inhibit T cell activation by
depleting tryptophan and arginine.12–14 With their naturally high Mφ:T cell ratios, these
cultures mimic an essential feature of tumor microenvironments. This provides a model to
assess immunomodulatory strategies for promoting immunity under conditions of myeloid
suppression.
In the studies described herein, we determined whether costimulation could increase the
PerC T cell response liberated by inhibiting iNOS. Since PerC Mφs have an immature
phenotype (MHC Class IIlo, B7lo), we reasoned that CD28 ligation would costimulate T
cells in these cultures.13,15 In contrast, we found that CD28 ligation suppressed the T cell
proliferative response. This observation is discussed with respect to the consideration of
myeloid-lymphoid ratios in experimental design when assessing the efficacy of
immunomodulatory drugs.
MATERIALS AND METHODS
Mice
Two- to four-month old male and female mice, bred and maintained at Rider University,
were handled in accord with NIH, Animal Welfare Act, and Rider University IACUC
guidelines. Breeding pairs of BALB/c, C57BL/6J, IFNγRKO (B6.129S7Ifngr/J), IL10KO
(B6.129P2-IL10tm1Cyn/J), iNOSKO (B6.129P2-Nos2tm1Lau/J), CD28KO (B6.129S2-
Cd28tm1Mak/J), CD40KO (B6.129P2-Cd40tm1Kik/J), and CD80/86KO or B7KO (B6.129S4-
Cd80tm1ShrCd86tm2Shr/J) mice were obtained from the Jackson Laboratory, Bar Harbor, ME.
PDL1KO mice were provided by the laboratory of Dr. Arlene Sharpe, Harvard Medical
School, Cambridge, MA.
Preparation of cell suspensions and cell culture
Lymph node (LN) cell suspensions were obtained by gentle disruption of the organ between
the frosted ends of sterile glass slides. Peritoneal cavity (PerC) cells were obtained by
flushing the peritoneum with 10 mls of warm (37°C) Hanks Balanced Salt Solution
supplemented with 3% FCS (Hyclone, Logan, UT). Viable cell counts were determined by
Trypan blue exclusion. Various dilutions (0.33 – 4.0 × 106/ml) of cells, in RPMI 1640
culture media (Life Technologies, Grand Island, NY) supplemented with 10% FCS, 0.1 mM
nonessential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml
gentamicin, 2 mM L-glutamine, 2 × 10−5 M 2-ME, and 10mM HEPES, were incubated in a
humidified atmosphere of 5% CO2 at 37°C in 96-well “U”-, “V”- or flat-bottom microtiter
plates (Corning Costar, Fisher Scientific). For anti-CD3 stimulation soluble anti-CD3ε mAb
(clone 145-2C11)16 (eBioscience, San Diego, CA), was added at 1.0 μg/ml. Where
exogenous costimulation was tested anti-CD28 (clone 37.51)17, or an isotype-matched
hamster IgG control (eBioscience) was added at 1.0 μg/ml or B7.1-Fc or B7.2-Fc (R&D
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tSystems, Minneapolis, MN) were added at 5.0–10.0 μg/ml. Mitogen (ConA) and
superantigen (Staphylococcal enterotoxin B, SEB) (Sigma Chemical, St. Louis,) were added
at 2 and 5 μg/ml, respectively. Anti-IFNγ mAb (XMG1.2, eBioscience) or anti-IL-10 mAb
(JES5-2A5, eBioscience) at 5–10 μg/ml were added at culture initiation. Based on prior
studies, to inhibit arginine catabolism in IFNγRKO mice the arginase (ARG) inhibitor N-w-
hydroxy-nor-L-arginine (1-NA; CalBiochem, San Diego, CA) was added; to inhibit arginine
catabolism in C57BL/6J mice the inducible nitric oxide synthase (iNOS) inhibitor NG-
monomethyl-L-arginine (1-MA; CalBiochem) was added.12,13 Optimal concentrations of all
reagents were determined in titration experiments. Proliferative responses were measure by
adding 1 μCi of [3H] thymidine (Moravek Radiochemicals, Brea, CA) after 44 hrs of
incubation. The plates were frozen 4 hrs after radiolabeling, then thawed for harvesting onto
filter paper mats using a semi-automated cell harvester (Skatron Instruments, Richmond,
VA). Radioactivity was measured by liquid scintillation spectrometry. For each experiment
3 – 5 wells were established for each test group.
IFNγ ELISpot
Following overnight incubation of cells plated as described above, IFNγ ELISpot assays
were conducted as described by the manufacturer (eBioscience).
Statistical analysis and costimulation index
T cell proliferative responses or number of IFNγ-secreting cells are presented as the average
CPM or cell number ± SEM. All data sets were compared using the Student’s t-Test with p
values below 0.05 defined as significant. The costimulation (or co-suppression when values
< 1.0) index is defined as the average costimulated (CD3 + CD28 stimulation) CPM divided
by the average control (CD3 stimulation alone) CPM. All results are representative of at
least three or more independent experiments that generated statistically valid results each
time they were conducted.
RESULTS
CD28 ligation costimulates lymph node but not peritoneal cavity T cells
Prior research has shown that resident macrophages (Mφs) suppress the activation of PerC T
cells.4,13 Mφ-mediated suppression in C57BL/6J PerC cell culture is blocked by the addition
of the inducible nitric oxide synthase (iNOS) inhibitor NG-monomethyl-L-arginine (1-MA).
Considering that resident PerC Mφs are CD80lo, CD86lo we reasoned that T cell
costimulation was limiting and that CD28 ligation could enhance the T cell activation
evidenced in PerC cell cultures treated with 1-MA.13 However the opposite result was
observed. While lymph node (LN) cell suspensions responded with an increase in T cell
proliferation to increasing concentrations of anti-CD28 (p < .005; Fig. 1A), PerC cells
exhibited a progressively diminished response (p < .05) relative to the control (1-MA alone,
no costimulation; Fig. 1B). Although a modest costimulatory response resulted from
reducing the number of PerC cells cultured this did not approach that seen with LN cells
(Fig. 1C versus 1D; Table 1). Co-suppression was most evident in PerC cultures that
increased Mφ-T cell interaction (“U”-bottom > “V”-bottom > flat-bottom microtiter wells;
Table 1). These results illustrate that cell culture composition and density can impact
interpretation of T cell costimulation biology.
CD28 ligation co-suppresses superantigen and CD3-independent T cell activation
The high frequency of T cells responsive to CD3 ligation invited speculation as to whether a
milder form of T cell stimulation would also be susceptible to CD28-mediated co-
suppression. This was the case with the superantigen Staphylococcus enterotoxin B (SEB),
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twhich triggered T cell proliferation in the presence of 1-MA and was co-suppressed by
CD28 ligation (Fig. 1E). T cell activation independent of CD3 engagement was tested using
the mitogenic plant lectin concanavalin A (ConA). This response was also co-suppressed
(Fig. 1E) indicating that regardless of how T cells were activated, ligation of the CD28
receptor can, under myeloid-enriched conditions, restrain T cell proliferation.
Co-suppression is not due to Fc binding by the anti-CD28 mAb
To address the possibility that the anti-CD28 mAb triggered suppression via Fc-binding, a
species- and isotype-matched, nonspecific mAb was tested. Unlike the hamster anti-CD28
mAb 37.51, the hamster nonspecific control mAb failed to co-suppress T cell proliferation
(Fig. 2A). PerC T cells from mice lacking the CD28 receptor (CD28KO) were not affected
by addition of the CD28 mAb and the addition of 1-MA did not increase their proliferation
(Fig 2A). Furthermore, the CD28-binding fusion proteins B7.1-Fc and B7.2-Fc both co-
suppressed the T cell proliferative response of C57BL/6J PerC cells (Fig. 2B). These
observations reinforced that the CD28 receptor can serve as a negative regulator of T cell
proliferation.
CD28 ligation co-suppresses BALB/c PerC T cells
Prior research has shown that BALB/c PerC T cells are less suppressed by resident Mφ than
those of C57BL/6J mice.4 Consistent with this observation, CD28 ligation co-suppressed
BALB/c PerC T cells less than C57BL/6J PerC T cells (CI = 0.65 versus 0.14; Fig. 3).
Regardless of the degree of co-suppression, this result illustrated that PerC T cells from two
widely studied strains of mice exhibit reduced proliferative responses following CD28
ligation.18,19
Role of IFNγ in CD28 co-suppression
Since costimulation is known to increase T cell cytokine production we assessed whether
increased production of a regulatory cytokine could be the mechanism for CD28-mediated
co-suppression.20 IL-10 and IFNγ are hallmark regulatory cytokines so the role of these
molecules was tested. The CD28-mediated co-suppression of PerC T cells from IL-10KO
mice was no different than that seen for wild type (C57BL/6J) mice (Fig. 4A). In contrast,
PerC T cells from IFNγRKO mice were less suppressed by Mφs and were costimulated by
CD28 ligation (Fig. 4B). Direct evidence in C57BL/6J mice that IFNγ plays a role in co-
suppression was provided by the observation that the addition of a neutralizing anti-IFNγ
mAb released PerC T cells from Mφ-suppression and negated CD28-mediated co-
suppression. Neutralizing mAbs for IL-10 and IL-4 had no effect on recovering the T cell
proliferative response (Fig. 4C).
CD28 ligation increases the number of IFNγ-secreting cells
IFNγ ELISpot assays were employed to measure the impact of CD28 ligation on IFNγ-
secreting cell (IFNγSC) number. CD28 ligation costimulated an increase in the number of
IFNγSCs, particularly at low cell density, and the addition of 1-MA had little effect,
particularly at increased cell density (Fig. 5A). Consistent with the observation of less co-
suppression of BALB/c PerC T cell proliferation (Fig. 3), there were fewer IFNγSC in this
strain (Fig. 5B). Although BALB/c PerC T cells consistently exhibited a greater
costimulatory response, C57BL/6J PerC cells always had the greater number of IFNγSC
(Fig. 5B). C57BL/6J PerC cells exhibited the greatest numbers of IFNγSC when a
neutralizing anti-IL10 mAb was included during their generation, particularly at high cell
density (Fig 5C). However, the greatest costimulatory increase in IFNγSC number followed
CD28 ligation of LN cells (CI = 7.75, Fig. 6A). This increase occurred without suppression
of LN T cell proliferation (Fig. 1). Likewise, IFNγRKO PerC T cells, which had greater
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tnumbers of IFNγSC than C57BL/6J mice, were costimulated for both proliferation (Fig. 4B)
and IFNγSC number (Fig. 6B). These results illustrate that while CD28 ligation increases
IFNγSC production, both the cellular composition and the cytokine milieu of the culture
determine whether the T cell proliferative response will be costimulated or co-suppressed.
Role of cell surface molecules in CD28 receptor-mediated co-suppression
IFNγ can increase the expression of molecules that either promote (CD40, CD80/B7.1,
CD86/B7.2) or inhibit (CD274/B7H1/PDL1) T cell activation.21 To determine if these
molecules have a role in the T cell biology described in the preceding experiments, the PerC
cells of CD40KO, B7KO, and PDL1KO mice were studied. While CD40KO and PDL1KO
mice exhibited co-suppression analogous to that of C57BL/6J mice (Fig. 7), the PerC T cells
of B7KO mice were more similar to those of CD28KO mice (Fig. 2A) in that the addition of
1-MA did not increase the T cell proliferative response (Fig. 7B). Furthermore, B7KO PerC
T cell proliferation was costimulated by CD28 ligation. Both CD28KO and B7KO mice had
fewer IFNγSC than wild type C57BL/6J mice (Fig. 8). Although costimulation significantly
increased IFNγSC number for the B7KO, the small number of these cells did not temper the
proliferative response (Fig. 7B). These data reinforce that the CD28-B7 receptor-ligand
pathway can trigger immune suppression via increased production of IFNγ.
CD28 receptor-mediated co-suppression requires iNOS
IFNγ has been shown to inhibit T cell proliferation by triggering Mφs to increase expression
of the arginine-consuming enzyme iNOS.11,13 To assess the role of iNOS in CD28-mediated
co-suppression, PerC T cells from iNOSKO mice were studied. The data show that iNOS is
essential for Mφ-mediated T cell suppression and that CD28-triggered co-suppression does
not occur for this strain (Fig. 9A). As a direct test of the role of iNOS in C57BL/6J mice,
their PerC cells were titered and tested for co-suppression with graded concentrations of the
iNOS inhibitor 1-MA. The data show co-suppression at the highest (1.0 × 105/well; CI ≤ .
30) and costimulation at the lower (0.33 and 0.11 × 105/well) concentrations of PerC cells
tested (Fig. 9B). However, co-suppression at the intermediate cell concentration (0.33 × 105/
well) returned as the inhibitor was diluted (CI values, relative to the 1 mM 1-MA control:
CI1.0 = 1.34, CI0.5 = .91, CI0.25 = .72, CI0.125 = .28). There was only costimulation at the
lowest PerC cell concentration (CI ≥ 2.03). These data reinforce that iNOS is the mechanism
for co-suppression and that cognate myeloid-lymphoid interaction is an essential element of
this form of T cell regulation.
DISCUSSION
The failure of PerC T cells to proliferate in response to CD3 ligation is not an intrinsic T cell
defect nor due to APC immaturity as T cell purification and PerC cell titration can rescue
this response (Fig. 1D).4,13 A surplus of natural costimulation, due to increased formation of
immunological synapses inherent to the APC-rich composition of PerC cells, triggered a
natural “braking system” with IFNγ production promoting iNOS expression, arginine
catabolism, and lymphocyte proliferative paralysis.11,14 CD28 ligation, rather than reversing
this pathway, supplemented the natural costimulatory response and increased IFNγ
production and immune paralysis. This “co-suppression” revealed the significance of the
myeloid:lymphoid composition of the cellular preparation targeted for costimulation. This
observation is particularly relevant to current efforts to deploy immunomodulatory drugs to
amend the aberrant immune regulation that is a hallmark of myeloid-rich tumor
microenvironments.22 In vitro screening assays that can reproduce the immunosuppressive
elements of tumor microenvironments will be essential to facilitate effective drug
development.5,10,23–28
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tThe same anti-CD28 mAb (clone 37.51, ref. 17) that all prior in vitro research has revealed
as costimulatory has been shown to inhibit T cell expansion and cytokine production in
vivo.29–31 Another anti-CD28 mAb (clone JJ319, ref. 32) tempers acute GVHD.33–35 In
these studies, CD28 blockade was thought to promote allograft tolerance by negating CD28/
B7 interaction or by allowing CTLA-4/B7 interaction to costimulate IFNγ production and
IDO/iNOS expression.31,34,35 Since CTLA-4 ligation has been shown to restrict IFNγ
production the tolerance observed more likely reflects a co-suppressive response, a
hypothesis validated by research showing that in vivo administration of the 37.51 mAb
activated T cells to produce the IFNγ essential for tolerance.31,36 Likewise, increased
numbers of IFNγSC and regulatory T cells (Tregs) were noted following in vivo
administration of the anti-CD28 mAb E18 and a monovalent Ab (Sc28AT) promoted
allograft tolerance by increasing IDO and Tregs.37,38 PerC Tregs are not a factor with in vitro
co-suppression because PerC cells from T cell-deficient nude and scid mice suppress
exogenous T cell proliferation via iNOS.13 The generation of Foxp3+ T cells is unlikely in
short-term culture, particularly with IFNγ and nitric oxide suppressing their
generation.14,39–42 There is evidence however, that IFNγ-generated regulatory APCs can
promote Treg development, a factor more likely in longer term, in vivo models of T cell
tolerance.43,44
In vivo administration of 37.51 to BALB/c mice afforded protection from lethal septic shock
via IL-10-mediated inhibition of TNFα production.45 This observation is consistent with the
T cell cytokine biology of BALB/c (Th2/IL10) versus (Th1/IFNγ) C57BL/6J mice. The
lower number of IFNγSC and less co-suppression witnessed with BALB/c PerC cells (Figs.
3, 5B) could be due to cytokine antagonism via autocrine IL-10 production by PerC B-1 B
cells or Bregs.23,46 In support of this premise, B-1 B cell-deficient BALB.xid mice have
PerC IFNγSC numbers more similar to C57BL/6J mice rather than to BALB/c mice and
exhibit co-suppression responses most like C57BL/6J mice.4 IL-10 still restrained PerC
IFNγSC production in C57BL/6J mice, particularly at higher cell density (Fig. 5C). These
results reinforce that culture density and cellular composition are important factors when
interpreting T cell suppression biology. Although the resolution of T cells into Th1/Th2/
Th17/Treg subsets is well established, the functional plasticity of Mφs confounds their
simple categorization as classically (M1) or alternatively activated (M2) cells.11,47,48 There
is growing appreciation for the heterogeneity of myeloid cells being a key factor in the
generation of distinct T cell subsets.49
Direct evidence that the CD28/B7 pathway can temper immunity came with the observation
that CD28KO and B7KO PerC T cells were not suppressed at culture densities that tempered
C57BL/6J and PDL1KO T cell proliferation (Figs. 2, 7). Peripheral T cell viability depends
upon the CD28/B7 pathway as both CD28KO and B7KO mice had reduced numbers of
PerC CD4+ and CD8+ T cells relative to C57BL/6J controls.4 PerC IFNγSC numbers were
low for both of these mutants (Fig. 8) and 1-MA was not required to inhibit iNOS and reveal
their proliferative response (Fig. 7). Even with costimulation, B7KO PerC IFNγSC numbers
did not reach the levels seen with BALB/c mice, which were sufficient to temper T cell
proliferation. Although the greatest number of IFNγSC were found in IFNγRKO mice their
PerC T cells responded to anti-CD3 and were costimulated by CD28 ligation (Fig. 6B)
revealing the critical role of IFNγ signaling for suppression. Although these results suggest
that T cells can be expanded in MΦ-rich environments, these cells may not be the IFNγ-
dependent effectors required for an optimal anti-tumor response. 41,50,51
That PDL1KO PerC T cells were suppressed was surprising considering that PDL1
expression has been shown to restrict T cell activation in lymphoid and normal tissue as well
as in tumors.52–54 Since PDL1 costimulates IL-10 production the absence of this ligand
likely enhanced IFNγ production and thus co-suppression (Fig. 5C).55 In a similar fashion,
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tfibroblastic reticular cells from PDL1KO mice were recently shown to have increased
IFNγ-dependent, iNOS-mediated T cell suppression relative to wild type control cells.56
Although the CI was lower for PDL1KO PerC T cells relative to the C57BL/6J control (Fig.
7B) the proliferative differences were not statistically significant between these groups.
Prior research has shown that neutralization of PDL1 on BALB/c Mφs leads to T cell
proliferative arrest by increasing IFNγ/iNOS production, however CD28 costimulation was
not assessed in this study.57 Although these results suggest that PDL1 is not a significant
factor in IFNγ-/Mφ-mediated suppression, this molecule and other B7 homologs are clearly
important in other regulatory pathways.2,54,58–61 The complexity and variety of T cell-APC
and T cell-T cell interactions among the B7 family members insure that there is more to
learn regarding this important family of costimulatory/co-inhibitory molecules.2,59–61
In summary, depending upon the myeloid composition of the target tissue, CD28 ligation
can suppress rather than costimulate T cell proliferation. Although this pathway may be
more potent than CTLA-4-Ig in controlling T cell activation, the “cytokine storm” that
ensued following in vivo trials of a superagonist anti-CD28 mAb might have tempered
enthusiasm for this strategy.31,62,63 This case certainly has made it clear that additional
models must be developed to assess the safety of immunomodulatory
biopharmaceuticals.64–67
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tFigure 1.
CD28 ligation costimulates lymph node T cell proliferation but suppresses the peritoneal
cavity T cell response. Panels A & B: effect of anti-CD28 concentration. 2 × 105 C57BL/6J
LN (A) or PerC cells, +/− 1-MA (B), were cultured with anti-CD3 +/− CD28 costimulation.
The numbers above the histograms are costimulation indices (CI) which represent the
average CPM for the costimulated response divided by the average CPM for the
uncostimulated response; for PerC cells CI values represent ratios of the costimulated PerC
+ 1-MA response to the control (uncostimulated) PerC + 1-MA response. * = p < .05; ** p
< .005. The addition of 1-MA had no effect on LN T cell proliferation; anti-CD28 in the
absence of anti-CD3 had no effect on LN or PerC T cell responses. Panels C & D: effect of
cell concentration on the CD28 costimulation response. Titered numbers of C57BL/6J LN or
PerC cells + 1-MA were cultured +/− CD28 costimulation. CI values reflect comparisons
within each cell concentration. Panel E: CD28 ligation co-suppresses the PerC T cell
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tresponse to SEB and ConA. 1.25 × 105 PerC cells, +/− 1-MA, were cultured with SEB or
ConA. CI values represent the ratios of the costimulated PerC + 1-MA response to the
control (uncostimulated) PerC + 1-MA response. LN responses to SEB were 17,597 ± 405
(− CD28) & 19,916 ± 409 (+ CD28) and to ConA were 42,977 ± 4314 (− CD28) & 38,604 ±
3395 (+ CD28). Each experiment is representative of at least three independent experiments
that yielded comparable, statistically valid results.
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tFigure 2.
CD28 triggered co-suppression is not due to Fc binding by the anti-CD28 mAb. For Panel
A, 1.25 × 105 C57BL/6J or CD28KO PerC cells +/− 1-MA were cultured with anti-CD3 +/−
anti-CD28 mAb costimulation or with an isotype- and species-matched, nonspecific mAb.
CI values represent the ratio of the costimulated PerC + 1-MA response to the control
(uncostimulated) PerC + 1-MA response. * = p < .05; ** p < .005. For Panel B, 1.0 × 105
C57BL/6J PerC cells were cultured with anti-CD3 + 1-MA alone or with CD28, B7.1Fc, or
B7.2Fc costimulation. CI values represent the ratio of the costimulated response to the
control (1-MA alone) response. Each experiment is representative of four independent trials
that produced similar results.
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tFigure 3.
CD28 ligation suppresses the BALB/c peritoneal cavity T cell proliferative response. 1.5 ×
105 C57BL/6J or BALB/c PerC cells +/− 1-MA were cultured with anti-CD3 +/− anti-
CD28. CI values represent the ratio of the CD28 costimulated response to the 1-MA alone
response. * = p < .05; ** p < .005. The data presented are representative of six independent
experiments that yielded similar results.
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tFigure 4.
Role of IL-10 and IFNγ in CD28 triggered co-suppression. For Panel A, 1.5 × 105 C57BL/
6J or IL10KO PerC cells +/− 1-MA were cultured with anti-CD3 +/− anti-CD28. For Panel
B, 1.5 × 105 C57BL/6J PerC cells +/− 1-MA or IFNγRKO PerC cells +/− the arginase
inhibitor 1-NA were stimulated with anti-CD3 +/− anti-CD28. CI values represent the ratio
of the CD28 costimulated response to the 1-MA or 1-NA (IFNγRKO) alone response. The
data presented are representative of three experiments with IL10KO mice and seven with
IFNγRKO mice. For Panel C, 1.25 × 105 C57BL/6J PerC cells alone or with 1-MA or with
neutralizing mAbs for either IFNγ, IL-4, or IL-10, were cultured with anti-CD3 +/− anti-
CD28 costimulation. The CI values represent the ratios of the CD28 costimulated response
to the 1-MA alone or the anti-cytokine mAb alone response. ** p < .005. The data presented
are representative of five independent trials that yielded similar results.
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tFigure 5.
CD28 ligation increases the number of peritoneal cavity IFNγ-secreting cells. For Panel A,
0.5 and 1.0 × 105 C57BL/6J PerC cells +/− 1-MA were cultured with anti-CD3 +/− anti-
CD28 as described in Methods. For Panel B, 0.75 and 1.5 × 105 C57BL/6J or BALB/c PerC
cells were cultured with anti-CD3 +/− anti-CD28. For Panel C, 1.0 and 1.5 × 105 C57BL/6J
PerC cells alone or with a neutralizing anti-IL-10 mAb were cultured with anti-CD3 +/−
anti-CD28 costimulation. All CI values represent the ratio of the costimulated response to
the uncostimulated response. * = p < .05; ** p < .005. The data shown are representative of
three separate experiments that generated similar results.
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tFigure 6.
CD28 ligation increases IFNγ-secreting cell number for cells that exhibit a proliferative
costimulatory response. For Panel A, 1.5 × 105 C57BL/6J PerC or LN cells were stimulated
with anti-CD3 +/− anti-CD28 costimulation. In Panel B, 1.0 x105 C57BL/6J or IFNγRKO
PerC cells were stimulated with anti-CD3 +/− anti-CD28 costimulation. CI values represent
the ratio of the costimulated response to the uncostimulated response. * = p < .05; ** p < .
005. The data shown are representative of three separate experiments that generated similar
results.
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tFigure 7.
CD28 ligation co-suppresses peritoneal cavity T cells from CD40KO and PDL1KO mice but
costimulates those from CD80/86KO (B7K0) mice. For both Panels, 1.5 x105 PerC cells +/−
1-MA were stimulated with anti-CD3 +/− anti-CD28 costimulation. CI values represent the
ratio of the CD28 costimulated response to the 1-MA treated, uncostimulated response. ** p
< .005. The data shown are representative of three independent CD40KO experiments &
eight separate PDL1KO experiments.
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tFigure 8.
CD28KO and B7KO mice have low numbers of IFNγ-secreting cells in their peritoneal
cavity. 1.5 x105 PerC cells were stimulated with anti-CD3 +/− anti-CD28. CI values
represent the ratio of the CD28 costimulated response to the control response. * p < .05. The
data shown are representative of three separate trials that yielded similar data.
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tFigure 9.
CD28 cosuppression requires iNOS. In Panel A, 1.5 x105 C57BL/6J or iNOSKO PerC cells
+/− 1-MA were stimulated with anti-CD3 +/− anti-CD28. CI values represent the ratio of the
CD28 costimulated response to the 1-MA treated, uncostimulated response. In Panel B,
titered numbers of C57BL/6J PerC cells cultured either alone or with titered concentrations
of 1-MA, were stimulated with anti-CD3 +/− anti-CD28. CI values represent the ratio of the
CD28 costimulated response to the 1-MA treated, uncostimulated response at the highest 1-
MA concentration (1.0 mM). For both panels * = p < .05; ** p < .005. The arrows in Panel
B indicate that the p values carry down the 1-MA titration series. The data shown in Panel A
are representative of five similar experiments, for Panel B for three similar experiments.
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Table 1
Costimulation Indices for Lymph Node and Peritoneal Cavity T Cells1
Lymph Node Cells2 0.66 × 105/well 0.22 × 105/well 0.07 × 105/well
Flat-Bottom 1.35 5.44 14.28
U- Bottom 1.31 1.61 3.14
V-Bottom 1.32 1.61 2.01
Peritoneal Cells3 0.66 × 105/well 0.22 × 105/well 0.07 × 105/well
Flat-Bottom 1.17 2.42 1.81
U- Bottom 0.66 0.83 1.20
V-Bottom 0.73 1.15 1.96
1
C57BL/6J LN or PerC cells were cultured with anti-CD3 + 1-MA (PerC) +/− anti-CD28. CI values determined as described in Methods; p values
reflect comparisons of +/− costimulation. C57BL/6J LN cells were 2–3% myeloid, 85–90% lymphoid (58% CD3+, CD4:CD8 = 1.13); PerC cells
were 40–45% myeloid, 25–30% lymphoid (18% CD3+, CD4:CD8 = 1.82)4
2
All LN values p < .005
3
Underlined PerC values p < .05
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